Logo for Oncternal Therapeutics Inc

Oncternal Therapeutics Investor Relations Material

Latest events

Logo for Oncternal Therapeutics Inc

Q2 2024

Oncternal Therapeutics
Logo for Oncternal Therapeutics

Q2 2024

8 Aug, 2024
Logo for Oncternal Therapeutics

Q1 2024

9 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Oncternal Therapeutics Inc

Access all reports
Oncternal Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies aimed at addressing cancers with critical unmet medical needs. Their diverse pipeline of treatments targets hematological malignancies and prostate cancer through multiple modalities. Their investigational product candidates include ONCT-808, an autologous CAR T cell therapy targeting ROR1 for patients with multiple hematologic and solid malignancies; ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI) for advanced prostate cancer; and Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in various malignancies. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.